Hyderabad, Sept. 27 -- The US proposed 100 pc tariff on branded and patented pharmaceutical imports is unlikely to have an immediate impact on Indian exports, said Pharmexcil Chairman Mr Namit Joshi. The bulk of our contribution lies in simple generics and most large Indian companies already operate U.S. manufacturing or repackaging units and are exploring further acquisitions, said Joshi in a statement.
"India has long been a cornerstone of the global supply chain for affordable, high-quality medicines, supplying nearly 47 percent of the U.S.'s pharmaceutical requirements, particularly in the generic drug market, he said.
Indian pharmaceutical companies continue to ensure the affordability and availability of essential medications- from ...